Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
NCT07363577 · NOVA2 Phase 3Recruiting
- Lead sponsor
- LB Pharmaceuticals Inc. (Industry)
- Enrollment
- 456 (estimated)
- Start date
- 25 Mar 2026
- Primary completion
- Jun 2027 (estimated)
- Study completion
- 1 Oct 2027
- Last update posted
- 27 Jul 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Sequential
- Masking
- Quadruple
- Arms
- 3
Interventions
- LB-102 (50 mg tablet) Drug
- LB-102 (100 mg tablet) Drug
- Placebo Other
Conditions and primary outcome
- Schizophrenia
Primary outcome
Change from baseline to Week 6 on the Positive and Negative Syndrome Scale (6 weeks)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07363577.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07363577 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.